BioMed Research International

Advanced Nanomaterials for Photothermal Biomedicine for Cancer and Cardiovascular Diseases

Publishing date
01 May 2020
Submission deadline
03 Jan 2020

Lead Editor
Guest Editors

1University College London, London, UK

2Shanghai Jiao Tong University School of Medicine, Shanghai, China

3Shanghai Institute of Ceramics, Chinese Academy of Sciences, China

This issue is now closed for submissions.

Advanced Nanomaterials for Photothermal Biomedicine for Cancer and Cardiovascular Diseases

This issue is now closed for submissions.


Nanomaterials in photothermal biomedicine have emerged as a hot trend in the field of biomedical research in recent years. Although they are still at the initial research stage, researchers are gradually furthering research into nanobiomedical materials. The uses of biomedical nanomaterials have evolved from initial medical imaging and diagnosis to the current integration of imaging, diagnosis, and treatment, consisting of cutting-edge technologies.

Cancer and cardiovascular diseases are both serious conditions that challenge the health and survival of people across the world. Photothermal therapy, as a minimally invasive and local treatment modality, avoids the multidrug resistance of patients and collateral damage to healthy cells and tissues that can result from traditional therapies. It therefore shows promise as an alternative treatment approach. The past few decades have witnessed great efforts dedicated to the synthesis and development of photothermal nanomaterials, which are drawing wide-spread attention due to their unique features such as low cost, facile synthesis, high photothermal conversion efficiency, good photostability, and fine-tune absorption spectrum. Recent progress in the synthesis of these kinds of nanomaterials has mainly concentrated on nanocomposites with synergistic effects, which requires complicated synthesis processes. The design and synthesis of such an effective platform with imaging and therapy function for the treatment of cancer and cardiovascular diseases remain challenging.

This special issue aims to provide a forum for the exchange of clinical and scientific information for the diagnostic and therapeutic nanomedicine community and allied professions involved in efforts to integrate imaging and photothermal therapy of cancer and cardiovascular diseases. Submissions concerning the fields of in vitro diagnostics and prognostics, in vivo imaging and therapeutics, and image-guided therapy are particularly welcomed. Both research and review articles that further the understanding and bridge the gap between related laboratory, clinic, and biotechnology industries are invited.

Potential topics include but are not limited to the following:

  • Design of biocompatible photothermal nanomaterials with photothermal capacity in near infrared region, with an application to cancer and cardiovascular diseases treatment
  • Simple synthesis methods (e.g., hydrothermal method, self-assembly method) to obtain biocompatible photothermal reagents with controllable properties, with focus on the efficacy of induced high temperature to inhibit the proliferation of cancer and vascular-associated cells
  • Validation of the efficacy of biocompatible photothermal nanomaterials in vitro for the treatment of cancer and cardiovascular diseases
  • Photothermal nanomaterials for in vivo imaging and therapy of cancer and cardiovascular diseases, such as multimodal imaging, image-guided phototherapy, and synergistic therapy, including photothermal therapy combined with chemotherapy, photothermal therapy combined with photodynamic therapy, and photothermal therapy combined with radiotherapy
BioMed Research International
 Journal metrics
See full report
Acceptance rate8%
Submission to final decision128 days
Acceptance to publication21 days
Journal Citation Indicator-
Impact Factor-
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.